Table 3.

Minimum inhibitory concentrations of these new hybrid compounds against E. coli BW25113 wild-type and mutant strains with impaired cell-wall structure (ΔdapF, ΔmrcB, ΔsurA) and efflux pumps (ΔacrB, ΔtolC).

Cpd.	Minimum Inhibitory Concentration [µg/mL]
	E. coli BW25113 WT 1	E. coli BW25113 ΔdapF	E. coli BW25113 ΔmrcB	E. coli BW25113 ΔsurA	E. coli BW25113 ΔacrB	E. coli BW25113 ΔtolC
3a	4	4	4	4	4	1
	(5.85 µM)	(5.85 µM)	(5.85 µM)	(5.85 µM)	(5.85 µM)	(1.46 µM)
3b	>64	>64	>64	>64	>64	16
	(>81.0 µM)	(>81.0 µM)	(>81.0 µM)	(>81.0 µM)	(>81.0 µM)	(20.3 µM)
7a	>64	>64	>64	>64	>64	2
	(>86.4 µM)	(>86.4 µM)	(>86.4 µM)	(>86.4 µM)	(>86.4 µM)	(2.70 µM)
7b	>64	>64	>64	>64	>64	2
	(>84.8 µM)	(>84.8 µM)	(>84.8 µM)	(>84.8 µM)	(>84.8 µM)	(2.65 µM)
11a	32	32	32	16	32	0.5
	(41.5 µM)	(41.5 µM)	(41.5 µM)	(20.7 µM)	(41.5 µM)	(0.65 µM)
11b	8	8	8	8	8	1
	(9.11 µM)	(9.11 µM)	(9.11 µM)	(9.11 µM)	(9.11 µM)	(1.14 µM)
CP 2	<0.03125	<0.03125	<0.03125	<0.03125	<0.03125	<0.03125
	(<0.0943 µM)	(<0.0943 µM)	(<0.0943 µM)	(<0.0943 µM)	(<0.0943 µM)	(<0.0943 µM)

¹ WT, wild-type; ² CP, ciprofloxacin.